For patients living with lymphoma, the journey toward remission is rarely a straight line. While initial treatment protocols often yield successful outcomes, the reality of "relapsed or refractory" (R/R) disease—where cancer returns or fails to respond to primary therapies—presents a complex set of clinical and emotional challenges. To address the urgent need for clarity and guidance in this space, the Lymphoma Research Foundation has announced a critical educational initiative: Ask the Doctor About Lymphoma: Navigating Relapsed/Refractory Disease.
This virtual symposium, scheduled for June 17, 2026, serves as a vital bridge between cutting-edge clinical research and the lived experience of patients and their families.
Main Facts: The Scope of the Virtual Symposium
The Ask the Doctor program is designed as a comprehensive, two-hour deep dive into the complexities of recurrent lymphoma and Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Unlike traditional lectures, the program is structured to prioritize interactivity, combining a foundational clinical overview with an extensive, expert-led question-and-answer session.
- Date: Wednesday, June 17, 2026
- Time: 4:00 PM – 6:00 PM ET
- Format: Virtual (Zoom), accessible via desktop, mobile device, or telephone.
- Target Audience: Patients, long-term survivors, care partners, and dedicated support networks.
The primary objective of the session is to demystify the "next steps" for patients facing treatment failure. By providing a platform where patients can interact directly with specialists, the foundation aims to empower individuals to make informed decisions about second- or third-line therapies, clinical trial participation, and supportive care options.
Chronology of Treatment: When Lymphoma Returns
The clinical trajectory of lymphoma is often categorized by the success of initial "first-line" therapies. However, when those therapies do not achieve the desired outcome, patients enter the "relapsed or refractory" landscape.
Defining the Terms
- Relapsed: The cancer had previously responded to treatment, but has now returned.
- Refractory: The cancer did not respond to the initial treatment (or responded only minimally) and continues to progress.
The Ask the Doctor program will guide participants through the decision-making timeline. This includes understanding why a particular treatment might stop working, the diagnostic tests required to re-evaluate the disease (such as PET/CT scans or biopsies), and how doctors determine the sequencing of subsequent therapies. By establishing a clear timeline of expectations, the program aims to alleviate the anxiety that often accompanies a shift in treatment strategy.
Supporting Data: The Evolving Landscape of Care
The landscape for treating R/R lymphoma has changed more in the last decade than in the previous fifty years. As the upcoming symposium will highlight, the era of relying solely on standard chemotherapy is being augmented by a surge in precision medicine.
Immunotherapy and CAR T-Cell Advances
Data from recent clinical trials suggest that patients with relapsed disease have more options than ever before. Chimeric Antigen Receptor (CAR) T-cell therapy, for instance, has revolutionized the prognosis for certain types of aggressive B-cell lymphomas. The program will touch upon how these "living drugs" work and which patient profiles are most likely to benefit.
The Role of Targeted Agents
Small molecule inhibitors, such as BTK inhibitors for CLL/SLL patients, have transformed chronic management strategies. Supporting data from the Lymphoma Research Foundation indicates that long-term survival is increasingly achievable even after multiple lines of therapy. However, the sheer volume of new drugs approved by the FDA can be overwhelming for patients. The June 17 session will provide a framework for navigating these options, emphasizing the importance of genomic testing and biomarker identification in selecting the right therapy.
Official Perspectives: The Role of Expert Guidance
The program will feature expert clinical insight, notably from figures like Dr. Elizabeth Brem, who has been instrumental in patient education initiatives. The inclusion of leading hematologist-oncologists ensures that the information shared is grounded in the latest evidence-based medicine.
The "Expert-Patient" Partnership
The Lymphoma Research Foundation underscores that the goal of this program is not to provide individual medical advice, but to foster "expert-patient" partnerships. "The most successful outcomes occur when a patient is fully informed about their disease biology and understands the rationale behind their treatment plan," notes the Foundation’s outreach literature.
The program organizers stress that while they provide a forum for high-level discussion, they maintain a strict policy: the information shared during the event is for educational purposes. Attendees are strongly encouraged to use the insights gained during the session to initiate detailed conversations with their own primary oncology teams.
Implications: Why This Program Matters
The implications of participating in such a symposium extend beyond clinical knowledge; they address the psychosocial burden of living with a chronic or recurring malignancy.
Empowering the Patient Voice
For many patients, the diagnosis of R/R lymphoma can feel like a loss of agency. By offering a platform to ask direct questions, the Ask the Doctor series helps restore a sense of control. Patients often report that the most valuable part of these sessions is learning that they are not alone and that their questions—no matter how complex—are shared by others in the community.
Supporting the Care Partner
The program is specifically designed to include care partners. The role of a caregiver for someone with relapsed cancer is taxing, requiring them to manage everything from side-effect monitoring to insurance logistics. Providing these individuals with an expert-led forum helps them better support their loved ones and reduces the isolation often felt by families navigating a cancer recurrence.
How to Participate and Access Resources
Registration for the event is currently open. The Lymphoma Research Foundation has streamlined the process to ensure accessibility for all, regardless of technical proficiency.
Registration Details
- Online Registration: Prospective attendees can register through the Foundation’s official website.
- Personal Assistance: Those who prefer a human touch can call the Foundation’s dedicated Helpline at 800-500-9976 or email their registration request to the support team.
- Post-Registration: Once registered, participants will receive a confirmation email containing the necessary Zoom links and dial-in instructions.
For Industry Professionals
The Foundation recognizes the importance of the pharmaceutical industry in the ongoing development of lymphoma therapies. While the session is primarily patient-focused, industry professionals interested in the educational programming may inquire about sponsorship opportunities to support the continuation of these vital services.
Conclusion: A Commitment to Long-Term Survivorship
As of 2026, the fight against lymphoma is characterized by rapid innovation and a shift toward personalized care. The Ask the Doctor About Lymphoma program on June 17 represents a vital link in the chain of patient support. By synthesizing complex medical data into actionable, patient-centered guidance, the Lymphoma Research Foundation continues to ensure that no patient has to navigate the difficult waters of relapse alone.
Whether you are currently managing a recurrence or are a survivor looking to stay informed on the latest therapeutic advancements, this program offers the tools, the community, and the expert perspective necessary to face the future with confidence.
Disclaimer: The information provided during Foundation programs is for informational or educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment from a qualified healthcare provider. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
